Related Experiment Video
Updated: Jan 25, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials
1Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA, 02111, USA.
Abstract:
Data from human dry and wet age-related macular degeneration (AMD) eyes support the hypothesis that constant 'tickover' of the alternative complement pathway results in chronic deposition of the complement membrane attack complex (MAC) on the choriocapillaris and the retinal pigment epithelium (RPE). Sub-lytic levels of MAC lead to cell signaling associated with tissue remodeling and the production of cytokines and inflammatory molecules. Lytic levels of MAC lead to cell death. CD59 is a naturally occurring inhibitor of the assembly of MAC. CD59 may thus be therapeutically efficacious against the pathophysiology of dry and wet AMD. The first gene therapy clinical trial for geographic atrophy - the advanced form of dry AMD has recently completed recruitment. This trial is studying the safety and tolerability of expressing CD59 from an adeno-associated virus (AAV) vector injected once into the vitreous. A second clinical trial assessing the efficacy of CD59 in wet AMD patients is also under way. Herein, the evidence for the role of MAC in the pathophysiology of dry as well as wet AMD and the scientific rationale underlying the use of AAV- delivered CD59 for the treatment of dry and wet AMD is discussed.
Insights
Constant complement system activation, forming the membrane attack complex (MAC), drives age-related macular degeneration (AMD). Inhibiting MAC with CD59 via gene therapy shows promise for treating both dry and wet AMD.
Area of Science:
- Ophthalmology
- Immunology
- Genetics
Background:
- Age-related macular degeneration (AMD) is linked to complement system overactivation.
- The alternative complement pathway's constant 'tickover' deposits the membrane attack complex (MAC) on ocular tissues.
- MAC, at sub-lytic or lytic levels, contributes to cellular dysfunction and death in AMD.
Purpose of the Study:
- To review the role of MAC in dry and wet AMD pathophysiology.
- To discuss the therapeutic potential of CD59, a MAC inhibitor, for AMD.
- To outline the rationale for using adeno-associated virus (AAV)-delivered CD59 in AMD treatment.
Main Methods:
- Review of existing data on complement pathway activation in AMD.
- Analysis of CD59's inhibitory function on MAC assembly.
- Examination of ongoing clinical trials using AAV-CD59 gene therapy for AMD.
Main Results:
- Evidence supports MAC deposition as a key factor in AMD progression.
- CD59 is a natural inhibitor of MAC, suggesting therapeutic value.
- Gene therapy trials delivering CD59 are underway for dry and wet AMD.
Conclusions:
- The complement system, specifically MAC, plays a critical role in both dry and wet AMD.
- AAV-mediated CD59 gene therapy presents a promising therapeutic strategy for AMD.
- Targeting MAC inhibition offers a novel approach to treating this vision-impairing disease.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Acid Attack on Concrete
The rate at which hydrogen...
What is a Hypothesis?
Sulfate Attack on Concrete
Sulfates from sources like soil, groundwater, or industrial effluents...

